Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT · NASDAQ Capital Market
+$0.46 today
Vol 0.89M · Avg 0.12M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-62.2%
avg -290.2%
ROIC
-42.3%
avg -282.2%
ROA
-47.2%
avg -184.4%
Analysis
ROIC is currently the strongest return metric at -42.3% versus its period average of -282.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Geordan G. Pursglove | Chief Executive Officer, President & Chairman | $210,000.00 | — | 38 | $350,000.00 | 3.02% |
Bastiaan van der Baan | Chief Scientific Officer | $174,000.00 | — | 54 | $11,000.00 | 0.09% |
Peter Stazzone | Chief Financial Officer | $62,000.00 | — | 74 | $50,000.00 | 0.43% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cingulate Inc.
CING
$28.65M
Allarity Therapeutics, Inc.
ALLR
$23.07M
Entero Therapeutics, Inc.
ENTO
$13.58M
Rocket One Inc.
HOTH
$13.52M
Lexaria Bioscience Corp.
LEXX
$12.27M
Kairos Pharma, Ltd.
KAPA
$9.69M
BriaCell Therapeutics Corp.
BCTX
$5.46M
Pulmatrix, Inc.
PULM
$5.30M
CASI Pharmaceuticals, Inc.
CASI
$2.33M
Clearside Biomedical, Inc.
CLSD
$2.15M
Who manages LIXT?
Lixte Biotechnology Holdings, Inc. (LIXT) lists 3 active executives. The top listed executive is Bastiaan van der Baan, Chief Scientific Officer.
Are LIXT insiders buying or selling?
Recent insider activity shows net buying of $5.63M.
Explore More
Continue the stock analysis
Jump to another research area for this company.